Neophyr (Nitric Oxide)

Nitric oxide activates soluble guanylate cyclase in pulmonary smooth muscle cells, raising cyclic GMP levels. The increased cGMP causes relaxation of the smooth muscle, leading to selective dilation of pulmonary vessels and a reduction in pulmonary arterial pressure.

The prescribed dose of Neophyr is determined by the treating physician based on the patient’s condition, response, and monitoring results. Dosage is individualized and adjusted during therapy to achieve the desired clinical effect.

Safety of inhaled nitric oxide in pregnancy or while breastfeeding has not been fully established. Use should be considered only if the potential benefit justifies any potential risk, and decisions are made by the healthcare provider.

To order Neophyr, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Neophyr delivers nitric oxide directly to the lungs, providing rapid and selective pulmonary vasodilation with minimal systemic effects. Compared with intravenous agents such as prostacyclin analogues, inhaled nitric oxide offers a faster onset and easier titration but requires specialized delivery equipment and monitoring.

Neophyr cylinders should be stored at ambient temperature, kept in their original packaging, protected from heat sources and direct sunlight, and secured to prevent movement. Follow all local regulations for medical gas storage and handling.

Neophyr is administered via a calibrated inhalation system that delivers a controlled concentration of nitric oxide gas mixed with oxygen or air. Administration is performed by trained healthcare professionals in a setting equipped for continuous monitoring of oxygenation, blood pressure, and methemoglobin levels.

The most serious risks include severe methemoglobinemia, which can impair oxygen delivery, and rebound pulmonary hypertension that may occur if the gas is stopped abruptly. Both conditions require prompt recognition and appropriate medical intervention.

Neophyr should be avoided in patients with known hypersensitivity to nitric oxide, those with significant anemia or G6PD deficiency, and individuals in whom rapid changes in pulmonary vascular tone could be hazardous without close monitoring.